News and Trends 4 Aug 2022
Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx
A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx…